Diferencia entre revisiones de «Erythromycin»

(Created page with "==General== *Type: *Dosage Forms: *Common Trade Names: ==Adult Dosing== ==Pediatric Dosing== ==Special Populations== *Pregnancy: *Lactation: *Renal Dosing **Adult **Pedia...")
 
(Remove disease-specific entries now covered by AntibioticDose (1 sections))
 
(No se muestran 13 ediciones intermedias de 6 usuarios)
Línea 1: Línea 1:
==General==
==General==
*Type:  
*Type: [[Is DrugClass::Macrolide]]
*Dosage Forms:
*Dosage Forms: PO, IV, topical
*Common Trade Names:  
*Common Trade Names:  


==Adult Dosing==
==Adult Dosing==
*250-500mg PO q6h
===Indications by Disease===
{{#ask: [[Has DrugName::Erythromycin]] [[Has Population::Adult]]
|?Treats disease=Disease
|?Has Dose=Dose
|?Has Context=Context
|format=table
|limit=50
|mainlabel=-
|headers=show
|sort=Treats disease
}}


==Pediatric Dosing==
==Pediatric Dosing==
*Mild-moderate infections: 30-50 mg/kg/day PO divided q6-8hr 
*Severe infection: 60-100 mg/kg/day PO divided q6-8hr
===Indications by Disease===
{{#ask: [[Has DrugName::Erythromycin]] [[Has Population::Pediatric]]
|?Treats disease=Disease
|?Has Dose=Dose
|?Has Context=Context
|format=table
|limit=50
|mainlabel=-
|headers=show
|sort=Treats disease
}}


==Special Populations==
==Special Populations==
*Pregnancy:
*[[Drug Ratings in Pregnancy|Pregnancy Rating]]: B
*Lactation:
*[[Lactation risk categories|Lactation risk]]: AAP categorizes as compatible with breastfeeding
*Renal Dosing
*Renal Dosing: No adjustment
**Adult
*Hepatic Dosing: Use caution
**Pediatric
*Hepatic Dosing
**Adult
**Pediatric


==Contraindications==
==Contraindications==
*Allergy to class/drug
*Allergy to class/drug
* QT prolongation


==Adverse Reactions==
==Adverse Reactions==
===Serious===
===Serious===
*Torsades, ventricular dysrhythmias
*Pseudomembranous colitis
*Hypertrophic pyloric stenosis
*Seizures


===Common===
===Common===
* nausea/vomiting
* diarrhea
* urticaria
* transaminitis
* urticarial rash


==Pharmacology==
==Pharmacology==
*Half-life:  
*Half-life: 2 hours
*Metabolism:  
*Metabolism: Liver
*Excretion:  
*Excretion: Bile/Renal
*Mechanism of Action:
*Mechanism of Action: Binds to 50S ribosomal unit → inhibiting protein synthesis
 
==[[Antibiotic Sensitivities]]<ref>Sanford Guide to Antimicrobial Therapy 2014</ref>==
{| class="wikitable"
| align="center" style="background:#f0f0f0;"|'''Group'''
| align="center" style="background:#f0f0f0;"|'''Organism'''
| align="center" style="background:#f0f0f0;"|'''Sensitivity'''
|-
| Gram Positive||[[Strep. Group A, B, C, G]]||I
|-
| ||[[Strep. Pneumoniae]]||I
|-
| ||[[Viridans strep]]||X1
|-
| ||Strep. anginosus gp||X1
|-
| ||[[Enterococcus faecalis]]||R
|-
| ||[[Enterococcus faecium]]||R
|-
| ||[[MSSA]]||I
|-
| ||[[MRSA]]||R
|-
| ||[[CA-MRSA]]||I
|-
| ||[[Staph. Epidermidis]]||I
|-
| ||[[C. jeikeium]]||R
|-
| ||[[L. monocytogenes]]||'''S'''
|-
| Gram Negatives||[[N. gonorrhoeae]]||I
|-
| ||[[N. meningitidis]]||X2
|-
| ||[[Moraxella catarrhalis]]||I
|-
| ||[[H. influenzae]]||I
|-
| ||[[E. coli]]||R
|-
| ||[[Klebsiella]] sp||R
|-
| ||E. coli/Klebsiella ESBL+||R
|-
| ||E coli/Klebsiella KPC+||R
|-
| ||[[Enterobacter]] sp, AmpC neg||R
|-
| ||[[Enterobacter]] sp, AmpC pos||R
|-
| ||[[Serratia]] sp||X1
|-
| ||Serratia marcescens||R
|-
| ||[[Salmonella]] sp||R
|-
| ||[[Shigella]] sp||R
|-
| ||[[Proteus mirabilis]]||X1
|-
| ||[[Proteus vulgaris]]||R
|-
| ||[[Providencia sp.]]||X1
|-
| ||[[Morganella sp.]]||X1
|-
| ||[[Citrobacter freundii]]||X1
|-
| ||[[Citrobacter diversus]]||X1
|-
| ||[[Citrobacter sp.]]||X1
|-
| ||[[Aeromonas sp]]||X1
|-
| ||[[Acinetobacter sp.]]||R
|-
| ||[[Pseudomonas aeruginosa]]||R
|-
| ||[[Burkholderia cepacia]]||R
|-
| ||[[Stenotrophomonas maltophilia]]||R
|-
| ||[[Yersinia enterocolitica]]||R
|-
| ||[[Francisella tularensis]]||X1
|-
| ||[[Brucella sp.]]||R
|-
| ||[[Legionella sp.]]||'''S'''
|-
| ||[[Pasteurella multocida]]||X1
|-
| ||[[Haemophilus ducreyi]]||'''S'''
|-
| ||[[Vibrio vulnificus]]||X1
|-
| Misc||[[Chlamydophila sp]]||'''S'''
|-
| ||[[Mycoplasm pneumoniae]]||'''S'''
|-
| ||[[Rickettsia sp]]||I
|-
| ||[[Mycobacterium avium]]||X1
|-
| Anaerobes||[[Actinomyces]]||'''S'''
|-
| ||[[Bacteroides fragilis]]||R
|-
| ||[[Prevotella melaninogenica]]||X1
|-
| ||[[Clostridium difficile]]||X1
|-
| ||[[Clostridium (not difficile)]]||I
|-
| ||[[Fusobacterium necrophorum]]||R
|-
| ||[[Peptostreptococcus sp.]]||I
|}
 
===Key===
{{Template:Antibacterial Spectra Key}}


==See Also==
==See Also==
*[[Antibiotics (Main)]]
*[[Antibiotics (Main)]]


==Source==
==References==
 
<references/>
<references/>
[[Category:Drugs]]
[[Category:Pharmacology]]
[[Category:ID]]

Revisión actual - 11:08 20 mar 2026

General

  • Type: Macrolide
  • Dosage Forms: PO, IV, topical
  • Common Trade Names:

Adult Dosing

  • 250-500mg PO q6h


Indications by Disease

DiseaseDoseContext
Acute diarrhea500mg PO BID x 5 daysCampylobacter
Bacterial conjunctivitisapplied to the conjunctiva q6hrs for 7 daysBacterial Conjunctivitis, Topical
Corneal abrasionointment qid x 3-5dNo Contact Lens
Lymphogranuloma venereum500mg PO QID x 21 daysAlternative
Pertussis500mg QID x7 daysAdults
Undifferentiated upper gastrointestinal bleeding3mg/kg IV over 20-30min, 30-90min prior to endoscopy; Achieves endoscopy conditions equal to lavage'"`UNIQ--ref-0000001F-QINU`"'Pre-endoscopy

Pediatric Dosing

  • Mild-moderate infections: 30-50 mg/kg/day PO divided q6-8hr
  • Severe infection: 60-100 mg/kg/day PO divided q6-8hr


Indications by Disease

DiseaseDoseContext
Acute diarrhea10mg/kg PO QID x 5 days (max 500mg/dose)Pediatric Campylobacter
Bacterial conjunctivitis0.5% ophthalmic ointment applied q6hrs x 7 daysPediatric
Corneal abrasion0.5% ointment applied QID x 3-5 daysPediatric
Diphtheria40mg/kg/day (max 2g/day)
Neonatal conjunctivitis0.5% ointment topical x1Prophylaxis at birth
Neonatal conjunctivitis50mg/kg PO daily in 4 divided doses x 14 daysChlamydial conjunctivitis
Pertussis10mg/kg PO QID x 14 days (max 2g/day)>1 month old
Pneumonia (peds)10mg/kg q6hrs1-3 month afebrile pneumonitis

Special Populations

Contraindications

  • Allergy to class/drug
  • QT prolongation

Adverse Reactions

Serious

  • Torsades, ventricular dysrhythmias
  • Pseudomembranous colitis
  • Hypertrophic pyloric stenosis
  • Seizures

Common

  • nausea/vomiting
  • diarrhea
  • urticaria
  • transaminitis
  • urticarial rash

Pharmacology

  • Half-life: 2 hours
  • Metabolism: Liver
  • Excretion: Bile/Renal
  • Mechanism of Action: Binds to 50S ribosomal unit → inhibiting protein synthesis

Antibiotic Sensitivities[1]

Group Organism Sensitivity
Gram Positive Strep. Group A, B, C, G I
Strep. Pneumoniae I
Viridans strep X1
Strep. anginosus gp X1
Enterococcus faecalis R
Enterococcus faecium R
MSSA I
MRSA R
CA-MRSA I
Staph. Epidermidis I
C. jeikeium R
L. monocytogenes S
Gram Negatives N. gonorrhoeae I
N. meningitidis X2
Moraxella catarrhalis I
H. influenzae I
E. coli R
Klebsiella sp R
E. coli/Klebsiella ESBL+ R
E coli/Klebsiella KPC+ R
Enterobacter sp, AmpC neg R
Enterobacter sp, AmpC pos R
Serratia sp X1
Serratia marcescens R
Salmonella sp R
Shigella sp R
Proteus mirabilis X1
Proteus vulgaris R
Providencia sp. X1
Morganella sp. X1
Citrobacter freundii X1
Citrobacter diversus X1
Citrobacter sp. X1
Aeromonas sp X1
Acinetobacter sp. R
Pseudomonas aeruginosa R
Burkholderia cepacia R
Stenotrophomonas maltophilia R
Yersinia enterocolitica R
Francisella tularensis X1
Brucella sp. R
Legionella sp. S
Pasteurella multocida X1
Haemophilus ducreyi S
Vibrio vulnificus X1
Misc Chlamydophila sp S
Mycoplasm pneumoniae S
Rickettsia sp I
Mycobacterium avium X1
Anaerobes Actinomyces S
Bacteroides fragilis R
Prevotella melaninogenica X1
Clostridium difficile X1
Clostridium (not difficile) I
Fusobacterium necrophorum R
Peptostreptococcus sp. I

Key

  • S susceptible/sensitive (usually)
  • I intermediate (variably susceptible/resistant)
  • R resistant (or not effective clinically)
  • S+ synergistic with cell wall antibiotics
  • U sensitive for UTI only (non systemic infection)
  • X1 no data
  • X2 active in vitro, but not used clinically
  • X3 active in vitro, but not clinically effective for Group A strep pharyngitis or infections due to E. faecalis
  • X4 active in vitro, but not clinically effective for strep pneumonia

See Also

References

  1. ↑ Sanford Guide to Antimicrobial Therapy 2014
Obtenido de «https://www.wikem.org/w/index.php?title=Erythromycin&oldid=386741»